CRNX

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Crinetics Pharmaceuticals Inc

NASDAQ | CRNX

45.56

USD

$0.00

(

0.00%

)

At Close (As of Nov 28, 2025)

$4.37B

Market Cap

-

P/E Ratio

-4.53

EPS

$60.34

52 Week High

$24.10

52 Week Low

HEALTHCARE

Sector

CRNX Chart

Recent Chart
Price Action

CRNX Technicals

Tags:

CRNX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$1.7M
Total Revenue $1M
Cost Of Revenue $2.8M
Costof Goods And Services Sold $2.8M
Operating Income -$339M
Selling General And Administrative $100M
Research And Development $240M
Operating Expenses $337M
Investment Income Net -
Net Interest Income $41M
Interest Income $41M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.8M
Income Before Tax -$298M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$298M
Comprehensive Income Net Of Tax -
Ebit -$339M
Ebitda -$336M
Net Income -$298M

Revenue & Profitability

Earnings Performance

CRNX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $1.4B
Total Current Assets $1.4B
Cash And Cash Equivalents At Carrying Value $265M
Cash And Short Term Investments $265M
Inventory -
Current Net Receivables $8.5M
Total Non Current Assets $59M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $0
Short Term Investments $1.1B
Other Current Assets $13M
Other Non Current Assets -
Total Liabilities $110M
Total Current Liabilities $60M
Current Accounts Payable $5.9M
Deferred Revenue -
Current Debt -
Short Term Debt $7.2M
Total Non Current Liabilities $50M
Capital Lease Obligations $52M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $52M
Other Current Liabilities $45M
Other Non Current Liabilities $829K
Total Shareholder Equity $1.3B
Treasury Stock -
Retained Earnings -$952M
Common Stock $2.3B
Common Stock Shares Outstanding $81M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$226M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $2.8M
Capital Expenditures $3.8M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$575M
Cashflow From Financing $1B
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$298M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$1.7M
Total Revenue $1M
Cost Of Revenue $2.8M
Costof Goods And Services Sold $2.8M
Operating Income -$339M
Selling General And Administrative $100M
Research And Development $240M
Operating Expenses $337M
Investment Income Net -
Net Interest Income $41M
Interest Income $41M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.8M
Income Before Tax -$298M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$298M
Comprehensive Income Net Of Tax -
Ebit -$339M
Ebitda -$336M
Net Income -$298M

CRNX News

CRNX Profile

Crinetics Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Crinetics Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing groundbreaking therapies for rare endocrine diseases and associated tumors. The company possesses a robust pipeline of innovative drug candidates, targeting significant unmet needs in the endocrine disorder market with both oral and targeted therapies. Crinetics is committed to advancing research and development efforts, positioning itself as a leader in specialized endocrine treatments, and striving to improve patient outcomes while transforming treatment paradigms in this vital healthcare sector.

LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
VINE
+10.76%
$0.39
HBI
-1.82%
$6.47
AMZE
+19.82%
$0.47
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
YGMZ
-9.59%
$0.11
BYND
-3.74%
$0.98
AXDX
-61.36%
$0.03
BMNR
+4.53%
$33.18
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
RUBI
-26.17%
$0.15
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
AMD
+3.93%
$214.24
SOND
-23.45%
$0.12
SNAP
+0.72%
$7.66
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
INHD
-0.97%
$0.22
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
CHR
-3.48%
$0.04
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
ONMD
+30.28%
$1.85
BMNU
+8.77%
$8.18
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.82%
$5.50
F
+0.45%
$13.25
TWOH
0.00%
$0.00
WLGS
-5.57%
$0.04
BURU
+10.43%
$0.24
GPUS
-8.58%
$0.30
MTSR
-0.35%
$70.50
IREN
+2.06%
$48.45
VALE
+0.79%
$12.61
SOFI
+4.31%
$29.72
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.80%
$4.64
GRAB
+2.44%
$5.45
ACHR
+4.40%
$7.82
DVLT
-4.69%
$2.03
AFMD
-34.94%
$0.18
PFE
0.00%
$25.71
SMX
+250.80%
$61.04
CRCL
+10.02%
$79.92
KWM
+13.63%
$0.75
DNN
-0.19%
$2.55
IBRX
+10.79%
$2.36
RIOT
+7.82%
$16.13
VEEE
+45.50%
$2.59
AMZN
+1.77%
$233.22
AAPL
+0.46%
$278.85
CAN
+9.78%
$1.01
WBD
+0.50%
$24.00
AIIO
-9.09%
$0.70
AG
+12.65%
$15.22
APLD
+8.66%
$27.10
GOOG
-0.05%
$320.12
NGD
+6.76%
$8.37
RIG
+2.09%
$4.39
GRYP
-10.38%
$1.38
BAC
+1.28%
$53.67
MODV
-25.22%
$0.43
RIVN
+4.20%
$16.86
KSS
+7.49%
$24.10
RR
-3.35%
$3.46
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
PLTR
+1.61%
$168.45
CDE
+6.76%
$17.28
ITUB
+1.82%
$7.80
AGNC
-0.66%
$10.49
CRCA
+19.56%
$4.40
KDLY
+7.20%
$0.49
T
+0.69%
$26.00
AMC
+6.30%
$2.44
NVO
+1.21%
$49.30
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.67%
$3.70
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
BTE
+2.05%
$3.22
LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
VINE
+10.76%
$0.39
HBI
-1.82%
$6.47
AMZE
+19.82%
$0.47
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
YGMZ
-9.59%
$0.11
BYND
-3.74%
$0.98
AXDX
-61.36%
$0.03
BMNR
+4.53%
$33.18
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
RUBI
-26.17%
$0.15
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
AMD
+3.93%
$214.24
SOND
-23.45%
$0.12
SNAP
+0.72%
$7.66
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
INHD
-0.97%
$0.22
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
CHR
-3.48%
$0.04
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
ONMD
+30.28%
$1.85
BMNU
+8.77%
$8.18
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.82%
$5.50
F
+0.45%
$13.25
TWOH
0.00%
$0.00
WLGS
-5.57%
$0.04
BURU
+10.43%
$0.24
GPUS
-8.58%
$0.30
MTSR
-0.35%
$70.50
IREN
+2.06%
$48.45
VALE
+0.79%
$12.61
SOFI
+4.31%
$29.72
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.80%
$4.64
GRAB
+2.44%
$5.45
ACHR
+4.40%
$7.82
DVLT
-4.69%
$2.03
AFMD
-34.94%
$0.18
PFE
0.00%
$25.71
SMX
+250.80%
$61.04
CRCL
+10.02%
$79.92
KWM
+13.63%
$0.75
DNN
-0.19%
$2.55
IBRX
+10.79%
$2.36
RIOT
+7.82%
$16.13
VEEE
+45.50%
$2.59
AMZN
+1.77%
$233.22
AAPL
+0.46%
$278.85
CAN
+9.78%
$1.01
WBD
+0.50%
$24.00
AIIO
-9.09%
$0.70
AG
+12.65%
$15.22
APLD
+8.66%
$27.10
GOOG
-0.05%
$320.12
NGD
+6.76%
$8.37
RIG
+2.09%
$4.39
GRYP
-10.38%
$1.38
BAC
+1.28%
$53.67
MODV
-25.22%
$0.43
RIVN
+4.20%
$16.86
KSS
+7.49%
$24.10
RR
-3.35%
$3.46
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
PLTR
+1.61%
$168.45
CDE
+6.76%
$17.28
ITUB
+1.82%
$7.80
AGNC
-0.66%
$10.49
CRCA
+19.56%
$4.40
KDLY
+7.20%
$0.49
T
+0.69%
$26.00
AMC
+6.30%
$2.44
NVO
+1.21%
$49.30
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.67%
$3.70
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
BTE
+2.05%
$3.22
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.